Anteris Technologies Global Corp. (NASDAQ:AVR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Anteris Technologies Global Corp. (NASDAQ:AVR) have been given an average recommendation of “Moderate Buy” by the five brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $16.00.

Several research analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 target price on shares of Anteris Technologies Global in a report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th.

Insider Activity

In related news, major shareholder L1 Capital Pty Ltd sold 558,633 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $8.20, for a total transaction of $4,580,790.60. Following the completion of the sale, the insider directly owned 6,633,314 shares of the company’s stock, valued at approximately $54,393,174.80. This represents a 7.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 3,008,459 shares of company stock valued at $25,243,576. 4.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AVR. BlackRock Inc. bought a new stake in shares of Anteris Technologies Global during the second quarter worth $56,846,000. ADAR1 Capital Management LLC lifted its position in Anteris Technologies Global by 205.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 3,789,132 shares of the company’s stock valued at $21,030,000 after acquiring an additional 2,550,355 shares in the last quarter. Perceptive Advisors LLC boosted its stake in Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after purchasing an additional 1,750,000 shares during the period. Nantahala Capital Management LLC acquired a new position in Anteris Technologies Global in the 2nd quarter worth $33,325,850. Finally, Affinity Asset Advisors LLC increased its holdings in Anteris Technologies Global by 87.5% during the 1st quarter. Affinity Asset Advisors LLC now owns 912,397 shares of the company’s stock worth $5,064,000 after purchasing an additional 425,713 shares in the last quarter.

Anteris Technologies Global Price Performance

Anteris Technologies Global stock opened at $7.62 on Thursday. The firm has a market capitalization of $742.65 million, a price-to-earnings ratio of -3.91 and a beta of 1.80. The company’s 50 day simple moving average is $8.59 and its 200 day simple moving average is $7.93. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The firm had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same period in the previous year, the company posted ($0.58) EPS. As a group, analysts predict that Anteris Technologies Global will post -1.21 EPS for the current fiscal year.

About Anteris Technologies Global

Anteris Technologies Global Corp. is a medical device company focused on developing advanced technologies for structural heart disease. Its primary product candidate is the DurAVR transcatheter heart valve, designed to treat aortic valve stenosis through a minimally invasive transcatheter aortic valve replacement procedure.

The DurAVR valve is based on Anteris’ ADAPT tissue-engineering technology and is manufactured as a single-piece valve intended to replicate the performance and natural hemodynamics of a healthy human aortic valve.